Scientists design and construct 10 large protein icosahedra to improve drug delivery: Using novel computational and biochemical approaches, scientists have accurately designed and built from scratch 10 large protein icosahedra--polyhedra with 20 faces--similar to viral capsids that carry viral DNA.
Sunday, July 24, 2016
Friday, July 8, 2016
Replacing saturated fats with unsaturated fats in diet can confer substantial health benefits: Consuming higher amounts of unsaturated fats was associated with lower mortality, according to a study from Harvard T.H. Chan School of Public Health.
Monday, June 20, 2016
Thalidomide was marketed as a sedative in West Germany and some other countries under the brand name "Contergan". 55 years ago, in 1961, it hit the headlines after having caused horrific deformations in unborn children. Between 5,000 and 10,000 children were affected worldwide. To this day, more than 2,000 victims across the world still live with the consequences of this tragedy. Soon after the discovery of these devastating side effects, the drug was withdrawn from the market. More recently, however, thalidomide is experiencing a kind of renaissance, as it was coincidentally discovered to inhibit the growth of certain tumors.
Since then, the two follow-up substances lenalidomide and pomalidomide have been approved for cancer treatment. Both thalidomide-derivatives are successfully used to treat certain bone-marrow cancers such as multiple myeloma. While showing stronger anti-tumor potential, they have fewer side effects than thalidomide. Despite this, they still pose a risk of causing severe birth defects and must not be taken during pregnancy.
Tuesday, May 31, 2016
Drexel scientists identify how two new antimalarial drugs work: Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite's skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream.
Monday, May 2, 2016
Sunday, April 24, 2016
Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis: A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab.
Monday, April 18, 2016
Rituximab shows second-line promise in autoimmune limbic encephalitis: Rituximab is an effective and well-tolerated second-line treatment for patients with autoimmune limbic encephalitis, suggests research.